Bluejay Nears Completion of Pivotal SYMON-II Sepsis Trial

The latest update is out from Bluejay Diagnostics ( (BJDX) ).

On April 7, 2026, Bluejay Diagnostics, Inc. reported that it has successfully enrolled 624 patients in its ongoing SYMON-II pivotal clinical trial, which is evaluating the Symphony IL-6 test for determining patient acuity in sepsis triage and monitoring in critical care settings. The trial targets 750 patients, and the company said it expects to complete enrollment within the next two to three months, noting that its inclusion and exclusion criteria have not led to significant patient exclusions.

SYMON-II is part of Bluejay’s broader SYMON clinical program, which includes pilot and pivotal studies designed to establish IL-6 levels associated with mortality and infection severity, and is intended to support a future 510(k) submission to the U.S. Food and Drug Administration. With enrollment in SYMON-II nearing completion, Bluejay signaled that it is moving closer to full clinical validation and subsequent regulatory steps for its Symphony IL-6 test, a critical path for bringing its rapid, near-patient sepsis diagnostic into the U.S. market and potentially strengthening its position in the critical care diagnostics segment.

The most recent analyst rating on (BJDX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.

Spark’s Take on BJDX Stock

According to Spark, TipRanks’ AI Analyst, BJDX is a Neutral.

The score is held down primarily by very weak financial performance (minimal revenue, persistent losses, and significant cash burn) and a bearish technical setup (below major moving averages with negative MACD). Positive corporate progress on the Symphony IL-6 program and manufacturing readiness provides some offset, but valuation remains constrained by loss-making fundamentals and no dividend support.

To see Spark’s full report on BJDX stock, click here.

More about Bluejay Diagnostics

Bluejay Diagnostics, Inc. is a medical diagnostics company developing the Symphony System, a cost-effective, rapid, near-patient testing platform aimed at sepsis triage and monitoring disease progression in critical care. Its lead product candidate, the Symphony IL-6 Test for sepsis, is designed to deliver accurate results in about 20 minutes to support earlier and better triage and treatment decisions, but it has not yet received U.S. regulatory clearance.

The company’s strategy centers on near-patient testing and real-time monitoring in acute care environments, positioning Symphony as a tool to help clinicians quickly assess patient severity and guide timely interventions. Bluejay must obtain authorization from the U.S. Food and Drug Administration before marketing Symphony as a diagnostic product in the United States, making successful clinical validation a key milestone for its commercialization path.

Average Trading Volume: 232,177

Technical Sentiment Signal: Sell

Current Market Cap: $2M

See more insights into BJDX stock on TipRanks’ Stock Analysis page.